Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS632 vs Omalizumab in healthy subjects
NCT04361812Phase 1Terminated
- Sponsor
- BioRay Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KSH001 in allergic asthma (2 arms), sponsored by BioRay Pharmaceutical. Primary endpoints: Area Under the Curve from Time Zero to Infinity at 13 weeks and Maximum Plasma Concentration at 13 weeks. Started Oct 2020; status: terminated.
02
Drugs
KSH001
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT04361812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361812.